1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethylethyl)-6-(ethylthio)-

CAS：1360105-53-8

Molecular Formula：

S-ETHYLISOTHIOUREA HYDROBROMIDE

CAS：1071-37-0

Molecular Formula：

6-chloro-2-methyl-2H-indazol-5-amine

CAS：1893125-36-4

Molecular Formula：

Dimethylthioformamide

CAS：758-16-7

Molecular Formula：C₃H₇NS

Dicobalt octacarbonyl

CAS：10210-68-1

Molecular Formula：Co2(CO)₈

2,3,4-Trihydroxybenzaldehyde

CAS：2144-08-3

Molecular Formula：C₇H₆O₄

DL-Serinohydrazide monohydrochloride

CAS：55819-71-1

Molecular Formula：C₃H₉N₃O₂.ClH

2,4,6-Tri(2,4-dihydroxyphenyl)-1,3,5-triazine

CAS：2125-23-7

Molecular Formula：C₂₁H₁₅N₃O₆

(R)-1-(tert-Butoxycarbonyl)-4-oxopyrrolidine-2-carboxylic acid

CAS：364077-84-9

Molecular Formula：C10H15NO5

Guanidine hydrochloride

CAS：50-01-1

Molecular Formula：CH5N3HCl

Dimethyl glutarate

CAS：1119-40-0

Molecular Formula：C₇H₁₂O₄

Propylphosphonic anhydride

CAS：68957-94-8

Molecular Formula：C₉H₂₁O₆P₃

1,1'-Thiocarbonyldi-2,2'-pyridone

CAS：102368-13-8

Molecular Formula：C₁₁H₈N₂O₂S

2-Chloro-4-methylpyrimidine

CAS：13036-57-2

Molecular Formula：C₅H₅ClN₂

Halquinol

CAS：8067-69-4

Molecular Formula：C₁₈H₁₁Cl₃N₂O₂

Polyadenylic acid potassium salt

CAS：26763-19-9

Molecular Formula：C10H13KN5O7P

11-26

Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel oxidative stress stabilizers for the treatment of ocular diseases, today announced that all primary and secondary endpoints of an ex-U.S. vehicle-cont

11-15

Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab

Clinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the Eu

11-09

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E

原料药进口

IMPORT OF APIS

中间体研发及生产

参比制剂进口

IMPORT OF REFERENCEPREPARATIONSINTERMEDI

兽药原料

VETERINARY DRUG RAW MATERIALS